Rhythm Pharmaceuticals, Inc.
NASDAQRhythm Pharmaceuticals enters September with a familiar tension: short sellers are adding pressure while analysts who cover the stock remain broadly constructive — and the stock sits roughly 25% below the Street's average target. Short interest has climbed meaningfully over the past month. It now represents 15.2% of the free float, up from around 14.1% a month ago and up 4.3% on…
RYTM put-call ratio plunges to 0.35, lowest in 52 weeks—4.1 standard deviations below its 20-day mean of 0.48. Bullish options positioning amid stock at $105.78, up 2.9% today despite short interest at 14.2% of float.
Snapshot as of 20 Sept 2026
Rhythm Pharmaceuticals enters September with a familiar tension: short sellers are adding pressure while analysts who cover the stock remain broadly constructive — and the stock sits roughly 25% below the Street's…
Rhythm Pharmaceuticals enters the back half of August with an unusual split: the analyst community is uniformly raising targets after a strong earnings print, while short sellers have quietly rebuilt positions to their…
Rhythm Pharmaceuticals reported earnings on August 4 and the options market reacted with one of the most aggressive bull shifts of the past year — making positioning the real story this week, not the result itself. The…
RYTM enters its June 24 earnings report with a notable split: short sellers have been quietly trimming positions, while options traders have swung to their most bullish stance in months. The options picture is the…
Rhythm Pharmaceuticals enters the back half of the week trading 10% higher, powered by a strong Q1 earnings beat that sent analysts scrambling to revise their models upward — while shorts hold their ground at the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RYTM — free to start on ORTEX.
Sign up for free →Open RYTM on ORTEX